Composition and application of anti-CD33 (Siglec-3) mAbs for the treatment of chronic hepatitis B virus infection
Publish time: 2021-11-30 00:00:00
Composition and application of anti-CD33 (Siglec-3) mAbs for the treatment of chronic hepatitis B virus infection
Docket Number
28A-1101015
Announcement Date
2021-11-30
IP Status
TW I857545、USP pending
Abstract
This inventions include following items: 1. compositions of anti-CD33 mAbs capable of inhibit CD33-HBV interaction; 2. activation of immune cells and induction of anti-HBsAg antibodies.
Technological Advantages
- Treatment of chronic hepatitis B virus infection.
- Prevention of hepatocellular carcinoma.
- Prevention of liver cirrhosis.
Applications of Technology
- Identification of anti-CD33 mAbs which are able to bind to CD33 specific domain to activate immune system to induce anti-HBsAg antibody.
- Ligation of ScFv region of anti-CD33 to human IgG Fc to increase potency to stimulate immune cell proliferation and production of induce anti-HBsAg antibody.
Inventor
Shie-Liang Hsieh, Pei-Shan Sung, An-Suei, Yang, Chung-Ming Yu
Contact person
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Composition and application of anti-CD33 (Siglec-3) mAbs for the treatment of chronic hepatitis B virus infection